Low level laser effect on improving the blood flow in diabetic foot ulcers

Effect of Low level laser with Ga-As (904 nm) on expression of angiogenic factors (VEGF, NO, VEGFR-2, HIF-1a), Oxygen saturation of peripheral blood and wound surface area in ischemic diabetic foot ulcers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014051717723N1

Enrollment

Registered

2015-05-08

Start date

2015-04-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabet Melitus Type 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: In Placebo group, Patients will be treated with standard therapy and laser,While it is turned off ,every other day, for 12 sessions. Intervention 2: In Laser therapy group,patients wil

Treatment - Devices

In Placebo group, Patients will be treated with standard therapy and laser,While it is turned off ,every other day, for 12 sessions.

In Laser therapy group,patients will be treated with Ga-As laser, 2 j/cm2, 90 mW and standard therapy, every other day, for 12 sessions.

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion: 1. Diabetic patients with ischemic diabetic foot ulcers (of both sexes) aged 40 to 60 years 2. 32> BMI> 25 3.Wagner grade 2 diabetic ulcers and ulcer size larger than the standard 2 cm below the ankle area 4. Mild to moderate neuropathic diabetic foot screening table (UK) 5. 0.50 ? Ankle Brachial Index < 0.9 6. HbA1c < 8 7. Non-smoking 8. No signs of wound infection 10. No Having kidney disease(serum creatinine level less than 2 mg / dL ) 11. No Having body fracture occurred recently. 12. No Having skin diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ankle Brachial Index. Timepoint: session 1 and 12. Method of measurement: Digital Manometer.;Oxygen saturation of peripheral blood. Timepoint: session 1 , 6,12. Method of measurement: Pulse oxymeter.;Wouns surface area. Timepoint: session 1 , 6,12. Method of measurement: Imaging.;Nitric Oxide. Timepoint: session 1 and 12. Method of measurement: biochemical analysis.;HIF-1a. Timepoint: session 1 and 12. Method of measurement: biochemical analysis.;Vascular Endothelial Growth Factor. Timepoint: session 1 and 12. Method of measurement: biochemical analysis.;Vascular Endothelial Growth Factor-Receptor 2. Timepoint: session 1 and 12. Method of measurement: biochemical analysis.	—

Measure

Time frame

Ankle Brachial Index. Timepoint: session 1 and 12. Method of measurement: Digital Manometer.;Oxygen saturation of peripheral blood. Timepoint: session 1 , 6,12. Method of measurement: Pulse oxymeter.;Wouns surface area. Timepoint: session 1 , 6,12. Method of measurement: Imaging.;Nitric Oxide. Timepoint: session 1 and 12. Method of measurement: biochemical analysis.;HIF-1a. Timepoint: session 1 and 12. Method of measurement: biochemical analysis.;Vascular Endothelial Growth Factor. Timepoint: session 1 and 12. Method of measurement: biochemical analysis.;Vascular Endothelial Growth Factor-Receptor 2. Timepoint: session 1 and 12. Method of measurement: biochemical analysis.

—

Secondary

Measure	Time frame
Assessment of physical activity and pain. Timepoint: Start and end of study. Method of measurement: standard Questionnaire SF-36.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Gity Torkaman

Tabiat Modarres Univercity

torkamg@modares.ac.ir+98 21 8288 4509

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026